Table 1: List
of KB220Z Ingredients with targets and mechanism of action.
|
Ingredient |
Therapeutic Target |
Mechanism |
|
L-Phenylalanine |
Dopamine
Synthesis |
20%
of this precursor amino-acid is converted to dopamine |
|
D-Phenylalanine |
Enkephalin/Endorphin Catabolism |
Inhibition
of the carboxypeptidase (enkephalinase);
thereby, increasing opioid peptide levels in brain |
|
L-Tyrosine |
Dopamine
Synthesis |
Rate-limiting
step in the synthesis of dopamine |
|
L-Glutamate |
GABA
Synthesis |
Supplied
in small amount to assist in balance of over-inhibiting GABA by natural
opioid peptides |
|
Chromium
Salts |
Serotonin
Synthesis |
Chromium
is known to increase the sensitivity of the insulin receptor thereby,
reducing the carbohydrate ratio by one-third in the blood; This effect causes
gut tryptophan to increase in the brain with a concomitant increase in
serotonin synthesis |
|
5-Hydroxytryptophane |
Serotonin
Synthesis |
Involved
in the synthetic pathway to produce serotonin |
|
Rhodiola rosea |
Enzyme
Inhibitor Increasing Catecholamines |
Rhodiola rosea has been shown to inhibit COMT activity thereby, increasing DA
in the synapse as well as inhibiting MAO-A in the mitochondria, which
increases vesicular DA in pre-synaptic neuron |
|
Pyridoxine
Phosphate |
Enzyme
Catalyst |
Assists
in the synthesis of dopamine |
|
Passion
Flower |
Benzodiazepine
Receptor Stimulant |
By
stimulating the benzodiazepine receptor, there is a reduction in anxiety due
to stress from detoxification |
Abbreviations: VTA: Ventral Tegmental Area; NMDA: N-Methyl-D-Aspartate; NAC: Nucleus Accumbens; DA:
Dopamine; COMT: Catecholamine-Methyl-Transferase; MAO-A:
Monoamine-Oxidase A